11,941 Shares in LifeStance Health Group, Inc. (NASDAQ:LFST) Bought by Stratos Wealth Partners LTD.

Stratos Wealth Partners LTD. purchased a new position in shares of LifeStance Health Group, Inc. (NASDAQ:LFST) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 11,941 shares of the company’s stock, valued at approximately $93,000.

A number of other hedge funds have also recently added to or reduced their stakes in the company. DekaBank Deutsche Girozentrale acquired a new position in LifeStance Health Group during the third quarter worth $34,000. Sunbelt Securities Inc. acquired a new position in LifeStance Health Group during the third quarter worth $34,000. Lazard Asset Management LLC raised its position in LifeStance Health Group by 117.8% during the third quarter. Lazard Asset Management LLC now owns 4,957 shares of the company’s stock worth $34,000 after acquiring an additional 2,681 shares during the period. Ameritas Investment Partners Inc. raised its position in LifeStance Health Group by 56.6% during the first quarter. Ameritas Investment Partners Inc. now owns 5,575 shares of the company’s stock worth $56,000 after acquiring an additional 2,016 shares during the period. Finally, Squarepoint Ops LLC acquired a new position in LifeStance Health Group during the fourth quarter worth $62,000. 85.50% of the stock is owned by hedge funds and other institutional investors.

LifeStance Health Group Price Performance

Shares of NASDAQ LFST opened at $5.69 on Thursday. The firm has a 50-day simple moving average of $6.54 and a 200-day simple moving average of $6.55. The stock has a market capitalization of $2.17 billion, a price-to-earnings ratio of -11.16 and a beta of 1.34. The company has a quick ratio of 1.11, a current ratio of 1.11 and a debt-to-equity ratio of 0.20. LifeStance Health Group, Inc. has a 52 week low of $4.74 and a 52 week high of $9.59.

LifeStance Health Group (NASDAQ:LFST) last released its quarterly earnings data on Wednesday, February 28th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by ($0.03). LifeStance Health Group had a negative return on equity of 12.66% and a negative net margin of 17.64%. The firm had revenue of $280.60 million for the quarter, compared to analyst estimates of $263.14 million. On average, equities analysts predict that LifeStance Health Group, Inc. will post -0.3 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have weighed in on LFST shares. Barclays upped their price objective on shares of LifeStance Health Group from $7.00 to $8.00 and gave the stock an “underweight” rating in a research report on Thursday, February 29th. The Goldman Sachs Group increased their target price on shares of LifeStance Health Group from $8.00 to $9.00 and gave the company a “neutral” rating in a research report on Monday, March 4th. Finally, Jefferies Financial Group increased their target price on shares of LifeStance Health Group from $8.00 to $9.00 and gave the company a “buy” rating in a research report on Wednesday, March 6th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and one has assigned a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $8.60.

Insider Buying and Selling

In related news, insider Kevin Michael Mullins sold 115,136 shares of the firm’s stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $8.02, for a total transaction of $923,390.72. Following the completion of the sale, the insider now directly owns 4,575,480 shares in the company, valued at $36,695,349.60. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In related news, insider Kevin Michael Mullins sold 115,136 shares of the firm’s stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $8.02, for a total transaction of $923,390.72. Following the completion of the sale, the insider now directly owns 4,575,480 shares in the company, valued at $36,695,349.60. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO David Bourdon sold 58,826 shares of the stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $6.93, for a total transaction of $407,664.18. Following the transaction, the chief financial officer now directly owns 433,856 shares of the company’s stock, valued at approximately $3,006,622.08. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 232,498 shares of company stock worth $1,709,985. Insiders own 8.50% of the company’s stock.

LifeStance Health Group Profile

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.